New study tests newborns for HIV at birth and starts early treatment
NCT ID NCT05393193
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study checks if testing high-risk babies for HIV right after birth and starting them on a modern antiretroviral drug (dolutegravir) can quickly control the virus. About 900 infants in Botswana will be tested at the hospital, and those with HIV will receive treatment and be followed for 96 weeks. The goal is to see if early diagnosis and treatment leads to better health outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Botswana Harvard Health Partnership
Gaborone, Botswana
Conditions
Explore the condition pages connected to this study.